A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Recruiting

Phase 3

UpadacitinibA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Sponsor:

AbbVie

Code:

NCT06012240

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 12 - 63

Healthy Volunteers: Not accepted

Interventions

Upadacitinib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-30. This information was provided to ClinicalTrials.gov by AbbVie on 2025-09-24.